Novo Nordisk Sues Eli Lilly Over 'Deceptive' National GLP-1 Advertising
The fierce commercial rivalry between the two giants of the GLP-1 market, Novo Nordisk A/S (NYSE: NVO) and Eli Lilly and Company (NYSE: LLY), has officially spilled into federal court. On July 21, 2026, Novo Nordisk filed a false-advertising lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, marking a major legal escalation in the battle for weight-loss and diabetes market share.
Novo Nordisk's complaint alleges that Eli Lilly is running a nationwide, multi-platform direct-to-consumer advertising campaign for its blockbuster drugs Zepbound (obesity) and Mounjaro (diabetes) that is "false and materially misleading" under the federal Lanham Act and state unfair-competition laws.
The Core Dispute: Comparative Dosing and "Outdated" Trials
At the heart of the lawsuit is how the two companies compare the efficacy of their competing drugs. Novo Nordisk argues that Eli Lilly's advertisements present a misleading picture of broad product superiority by comparing Lilly's highest approved doses to lower, outdated doses of Novo's medications.
Specifically, Novo Nordisk's complaint points to two major discrepancies:
- Wegovy Dosing (Obesity): Novo Nordisk claims that Lilly's advertisements compare the highest doses of Zepbound (10 mg and 15 mg) to Wegovy's lower 1.7 mg and 2.4 mg doses, while completely omitting or burying the fact that Wegovy is now approved at a higher, more effective dose of 7.2 mg (approved in early 2026 following the successful STEP UP trial).
- Ozempic Dosing (Diabetes): Novo Nordisk alleges that Lilly's Mounjaro ads compare Mounjaro's highest 15 mg dose to Ozempic's lowest 1 mg dose, rather than Ozempic's highest approved 2 mg dose.
John F. Kuckelman, Novo Nordisk's Senior Vice President and Group General Counsel, summarized the company's position:
"Healthcare companies have a responsibility to keep their public claims accurate and current — ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns."
Novo Nordisk is seeking a permanent injunction requiring Eli Lilly to remove the disputed advertisements from all platforms and launch a corrective advertising campaign. Novo has also threatened to seek an immediate preliminary injunction if Lilly does not voluntarily withdraw the campaigns.
Eli Lilly's Defense: The SURMOUNT-5 Trial
Eli Lilly has vigorously rejected Novo Nordisk's claims, standing firmly behind its advertising campaigns. Lilly argues that its comparative claims are grounded in robust, published scientific evidence from its SURMOUNT-5 clinical trial.
SURMOUNT-5 remains the only randomized, head-to-head clinical trial directly comparing tirzepatide (Zepbound) and semaglutide (Wegovy) for chronic weight management. The trial evaluated patients taking 10 mg or 15 mg of Zepbound against those taking 1.7 mg or 2.4 mg of Wegovy (which were the standard maximum tolerated doses when the trial was conducted and completed in 2024).
An Eli Lilly spokesperson defended the company's marketing strategy:
"Rather than compete on the merits of its products, Novo Nordisk is asking a court to stop Eli Lilly from communicating the results of that trial. We stand firmly behind our advertising. It is truthful, it is transparent, and it is grounded in the most direct scientific evidence available — exactly what patients deserve."
Market Context and Fallout
This legal clash highlights the intense pressure on both companies as they defend their multi-billion dollar franchises. While Eli Lilly has continued to capture market share with its injectable tirzepatide portfolio (which saw Mounjaro and Zepbound combine for nearly $15 billion in Q2 2026 sales), Novo Nordisk is under pressure from U.S. pricing erosion.
Since the lawsuit was filed on July 21, 2026, Novo Nordisk shares have slipped roughly 6% to 8%, while Eli Lilly shares have climbed nearly 4%, reflecting Wall Street's perception of Lilly's ongoing commercial momentum.